New Delhi, Jun 11 (PTI) A Gurugram hospital on Thursday inaugurated what it described as India’s first Centre of Excellence for Myeloma and Lymphoma, aimed at providing specialised and integrated care for blood-cancer patients.
Fortis Memorial Research Institute (FMRI), Gurugram, said the centre will bring together experts in haematology, haemato-oncology, pathology, genomics, radiation oncology, stem-cell transplantation, cellular therapies and clinical research on a single platform.
According to the hospital, the disease-focussed centre has been established to address the growing complexity of blood-cancer treatment through personalised care pathways, multidisciplinary collaboration and access to advanced diagnostics and therapies.
Dr Rahul Bhargava, Principal Director and Chief, Haematology, Haemato-Oncology and Bone Marrow Transplant at FMRI, said the initiative seeks to create an ecosystem where scientific discoveries can be translated into personalised treatment strategies for patients.
“The centre brings together expertise across genomics, genetics, pathology, translational science, haematology, radiation oncology, cellular therapy, CAR-T and clinical research, giving patients access to advanced diagnostics, therapies and clinical innovations,” he said.
Dr Shrinidhi Nathany, Consultant, Molecular Haematology and Oncology, said genomic profiling is increasingly helping doctors understand blood cancer at a molecular level and enabling more personalised treatment approaches.
“Advanced genomic testing allows us to identify actionable mutations, monitor the disease more precisely and connect patients to targeted therapies and clinical trials,” Nathany said.
Senior Vice President and SBU Head of FMRI Yash Rawat said the centre is expected to serve as a referral hub for patients seeking specialised treatment for myeloma and lymphoma, while also contributing to clinical research and physician education.
The hospital said the initiative aims to improve clinical outcomes, accelerate access to innovation and strengthen research in the field of haematologic oncology. PTI SGV RC
This report is auto-generated from PTI news service. ThePrint holds no responsibility for its content.